BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19580341)

  • 1. Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
    Mego M; Rejlekova K; Reckova M; Sycova-Mila Z; Obertova J; Rajec J; Mardiak J
    Neoplasma; 2009; 56(5):398-403. PubMed ID: 19580341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
    Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
    Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
    Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
    J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
    J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors.
    von Eyben FE; Blaabjerg O; Hyltoft-Petersen P; Madsen EL; Amato R; Liu F; Fritsche H
    Clin Chem Lab Med; 2001 Jan; 39(1):38-44. PubMed ID: 11256799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ; Norman AR; Dearnaley DP; Horwich A
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
    J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
    Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
    Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
    Fresneau B; Orbach D; Faure-Conter C; Sudour-Bonnange H; Vérité C; Gandemer V; Pasquet M; Fasola S; Rome A; Raimbault S; Martelli H; Frappaz D; Le Teuff G; Patte C
    Eur J Cancer; 2018 May; 95():11-19. PubMed ID: 29604495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features and survival of testicular tumours in a Southeast Asian university hospital: a ten-year review.
    Tan GH; Azrif M; Shamsul AS; Ho CC; Praveen S; Goh EH; Bahadzor B; Ismail F; Zulkifli MZ
    Asian Pac J Cancer Prev; 2011; 12(10):2727-30. PubMed ID: 22320982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P; Hogan SJ; Bliss JM; Horwich A
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extragonadal germ cell tumors in Japan.
    Ebi H; Nakata M; Tahara M; Igarashi T; Kawada K; Itoh K; Ueda R; Minami H
    Cancer Sci; 2003 Dec; 94(12):1107-11. PubMed ID: 14662028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.